Labomar SpA, a global player in the nutraceuticals sector and a specialist in research, development, and contract manufacturing of dietary supplements, pharmaceuticals, medical devices, and foods, has acquired 97.85% of Pharmia Holding Oy’s share capital. Pharmia is Finland’s leading CDMO (Contract Development and Manufacturing Organization) focused on the development and production of dietary supplements, probiotics, and medical devices.
“Welcoming Pharmia into our group is a source of great satisfaction and marks an important step in our international growth strategy,” commented Walter Bertin, founder and Chief Executive Officer of Labomar.
Pharmia holds a leadership position in the Nordic countries with strong know-how in probiotic development and medical devices. The company consistently allocates 5% of its revenue to research and development, continuing to strengthen operational efficiency and establishing itself as a strategic partner for numerous international players.
The deal will enable Labomar, a company long oriented toward innovation, health-solutions development, and a diversified global presence, to continue expanding its R&D capabilities—particularly in medical devices and probiotics—and to benefit from a privileged position in a high-potential geographic region.
Expansion into the Nordic market will also allow Labomar to consolidate its international footprint in nutraceuticals and medical devices, broadening its customer base and generating new synergies in terms of innovation and product development.
“We are meeting a team that shares our approach to innovation and quality, and that will enable us to strengthen our position in a market rich with opportunities, where we can build lasting relationships with the major players and guide them toward increasingly advanced solutions. The strength of Pharmia’s management team and its production capacity will also allow us to rapidly integrate activities and accelerate the development path we are charting at the European level,” adds Bertin.
Petteri Laaksomo, CEO of Pharmia Holding Oy, states: “We are proud to join the Labomar family. This transaction represents a fundamental strategic milestone for our mission to consolidate our Nordic presence and further strengthen our capabilities in the development of high-quality nutraceuticals and medical devices. The excellence and values that define Labomar align fully with ours. Together, we look to the future with the aim of driving innovation and creating even greater value for our partners and customers.”
Subscribe to Karla Miller
